Konstantinos Stathogiannis

Dr. Konstantinos Stathogiannis

orcid
THV Greece, Hygeia Hospital, Athens, Greece

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2012 in JACC
Verified
Journal Article
Closed access
KTKonstantinos Toutouzas
Konstantinos Toutouzas
CGCharalampos Grassos
Charalampos Grassos
MDMaria Drakopoulou
Maria Drakopoulou
ASAndreas Synetos
Andreas Synetos
ETEleftherios Tsiamis
Eleftherios Tsiamis
CSChristodoulos Stefanadis
Christodoulos Stefanadis

25 June 2025 in JACC: Cardiovascular Interventions
Verified
Journal Article
Open access
Domenico AngellottiDomenico Angellotti
Domenico Angellotti
IMIsabel Mattig
Isabel Mattig
DSDaryoush Samim
Daryoush Samim
BGBjörn Goebel
Björn Goebel
CJCharlotte Jantsch
Charlotte Jantsch
Fabien PrazFabien Praz
Fabien Praz
Transcatheter tricuspid valve replacement (TTVR) has been recently approved for the treatment of patients with severe tricuspid regurgitation (TR). Real-world evidence regarding the commercial use of TTVR is lacking. The aim of this study was to investigate the real-world safety and efficacy of the EVOQUE TTVR system in patients with severe TR treated at 12 experienced heart valve centers in 5 European countries. Consecutive patients treated with the EVOQUE system since approval in Europe (October 2023 to February 2025) were included in this retrospective analysis. Clinical outcomes were assessed at 30-day follow-up. The study included 176 patients (mean age 77.8 years, 72.0% women, median TRI-SCORE 5 points [IQR: 2 points]). At a median follow-up time of 30 days (IQR: 2 days), severe or greater TR was reduced to mild or none in 126 of 128 patients (98.4%; P < 0.001). NYHA functional class improved from 20.2% (28 of 138) class I or II at baseline to 79.7% (110 of 138; P) at 1 month (P < 0.001), with signs of improved hepatorenal function (estimated glomerular filtration rate 47.0 ± 19.9 mL/min/1.73 m2 vs 53.7 ± 23.3 mL/min/1.73 m2 [P < 0.001]; bilirubin 14.2 ± 8.8 μmol/L vs 11.0 ± 9.8 μmol/L [P < 0.001]). Massive or torrential TR at baseline was more common among patients who improved compared with those with stable or worsening NYHA functional class (75 of 98 [76.5%] vs 20 of 40 [50.0%]; P = 0.004). Permanent pacemaker implantation was required in 21 of 111 pacemaker-naive patients (18.9%), in particular those with conduction disturbances at baseline (OR: 4.53; 95% CI: 1.73-11.82; P = 0.002). Moderate or severe right ventricular dysfunction was an independent predictor of clinical failure at 1-month follow-up (OR: 3.60; 95% CI: 1.39-9.32, P = 0.008). TR elimination following TTVR in a real-world setting was associated with significant symptom and end-organ functional improvement. Patients with massive or torrential TR were more likely to experience functional improvement. Pre-existing conduction disturbances are associated with increased risk for pacemaker implantation, while baseline right ventricular dysfunction is a strong predictor of adverse clinical outcomes.

1 June 2012 in JACC: Cardiovascular Interventions
Verified
Journal Article
Closed access
KTKonstantinos Toutouzas
Konstantinos Toutouzas
AKAntonios Karanasos
Antonios Karanasos
Konstantinos StathogiannisKonstantinos Stathogiannis
Konstantinos Stathogiannis
ASAndreas Synetos
Andreas Synetos
ETEleftherios Tsiamis
Eleftherios Tsiamis
CSChristodoulos Stefanadis
Christodoulos Stefanadis

22 April 2025 in Circulation
Verified
Journal Article
Closed access
AVAndrew M. Vekstein
Andrew M. Vekstein
ZWZachary K. Wegermann
Zachary K. Wegermann
PMPratik Manandhar
Pratik Manandhar
MMMichael J. Mack
Michael J. Mack
DCDavid J. Cohen
David J. Cohen
SVSreekanth Vemulapalli
Sreekanth Vemulapalli
BACKGROUND: Real-world low-risk transcatheter aortic valve replacement (TAVR) outcomes in the United States have not been assessed comprehensively versus pivotal trials, which is a key component of measuring the quality of clinical technology adoption. METHODS: We identified heart team–designated low-risk patients undergoing TAVR for trileaflet severe, symptomatic aortic stenosis in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Registry, as well as a subset of patients who met low-risk trial inclusion and exclusion criteria, from January 2020 to March 2024. Outcomes (mortality, stroke, new pacemaker, and “alive and well,” defined as alive at 1 year with Kansas City Cardiomyopathy Questionnaire score ≥60 and ≤10-point decrease from baseline) at 30 days and 1 year were assessed. Multivariable models were developed to assess predictors of death and stroke within 1 year after TAVR. RESULTS: Among 383 030 patients who underwent TAVR during the study period, 108 407 (28%) were designated low-risk by the heart team, and 68 194 (18%) met other study inclusion and exclusion criteria. Of these, 62% (n=42 093) would have been eligible for the low-risk trials. In the overall heart team–designated low-risk population, 30-day outcomes included 0.8% mortality, 1.5% stroke, and 8.4% new permanent pacemaker requirement; 1-year outcomes included 4.6% mortality, 2.6% stroke, and 90% alive and well. In the trial-eligible population, 0.6% mortality, 1.4% stroke, and 8.0% new permanent pacemaker requirement had occurred by 30 days; values at 1 year included 3.1% mortality, 2.4% stroke, and 92% alive and well. Notable multivariable predictors of 1-year mortality were atrial fibrillation, nontransfemoral access, and lower baseline Kansas City Cardiomyopathy Questionnaire score. CONCLUSIONS: One-year outcomes among real-world trial-eligible patients are excellent, but adverse events are higher compared with published clinical trial data, likely because of greater comorbidity burden and lower baseline Kansas City Cardiomyopathy Questionnaire score. These data can help inform expected outcomes and health status after low-risk TAVR.

1 June 2013 in Current Topics in Medicinal Chemistry
Verified
Journal Article
Closed access
PDF file
ASAndreas Synetos
Andreas Synetos
KTKonstantinos Toutouzas
Konstantinos Toutouzas
Konstantinos StathogiannisKonstantinos Stathogiannis
Konstantinos Stathogiannis
George LatsiosGeorge Latsios
George Latsios
ETElefterios Tsiamis
Elefterios Tsiamis
CSChristodoulos Stefanadis
Christodoulos Stefanadis
Arterial hypertension is an epidemic currently affecting almost a billion people worldwide. The consequences from high blood pressure vary, from peripheral arterial disease and chronic kidney failure to acute myocardial infarction and stroke. MicroRNAs (miRNAs) are small non-coding RNA molecules comprised of 22-26 nucleotides and provide posttranscriptional protein expression regulation. The many biological processes in which they are implicated, such as cell proliferation, apoptosis, metabolism, cell differentiation and morphogenesis confirms the functional significance of miRNAs. It has been found that miRNAs are expressed in cardiovascular disorders and seem to be important players in the pathogenesis of arterial hypertension. The elucidation of which miRNAs are key players and at what level is of high value since it is necessary in order to better understand the mechanisms underlying hypertension, thus leading to better diagnostic modalities and therapeutic regimes.

26 September 2012 in Heart
Verified
Journal Article
Closed access
PDF file
KTKonstantinos Toutouzas
Konstantinos Toutouzas
MDMaria Drakopoulou
Maria Drakopoulou
CAConstantina Aggeli
Constantina Aggeli
CNCharalampia Nikolaou
Charalampia Nikolaou
IFIoannis Felekos
Ioannis Felekos
CSChristodoulos Stefanadis
Christodoulos Stefanadis
Objectives Both neoangiogenesis and inflammation contribute in atherosclerosis progression. Contrast-enhanced ultrasound (CEUS) provides visualisation of plaque neovascularisation. Microwave radiometry (MR) allows in vivo non-invasive measurement of temperature of tissues, reflecting inflammatory activation. We assessed the association of carotid plaque temperature, measured by MR, with plaque neovascularisation assessed by CEUS in intermediate lesions. Methods Consecutive patients with coronary artery disease and carotid atherosclerosis underwent carotid ultrasound imaging, CEUS and MR. Plaque texture, plaque surface and plaque echogenicity were analysed. Contrast enhancement (CE) by CEUS was defined as the % percentage of signal intensity difference, prior and post contrast infusion. Thermal heterogeneity (ΔT) was assigned as maximal temperature along the carotid artery minus minimum. Results Eighty-six carotid arteries of 48 patients were included. Fatty plaques had higher CE% and ΔT compared with mixed and calcified (p<0.01 for all comparisons). Heterogeneous plaques had higher CE% and ΔT compared with homogenous (p<0.01 for all comparisons). Plaques with irregular surface had higher CE% and ΔT compared with plaques with regular (p<0.01 for all comparisons). There was a good correlation between ΔT and CE (R=0.60, p<0.001). Conclusions Carotid plaque neovascularisation on CEUS examination is associated with increased thermal heterogeneity and ultrasound characteristics of plaque vulnerability in intermediate lesions.